Neonc Technologies (NTHI) to Release Earnings on Friday

Neonc Technologies (NASDAQ:NTHI) is anticipated to release its results before the market opens on Friday, March 20th. Analysts expect Neonc Technologies to post earnings of ($0.37) per share for the quarter.

Neonc Technologies Trading Up 3.2%

Shares of NTHI traded up $0.28 during mid-day trading on Monday, reaching $8.93. 51,488 shares of the company’s stock were exchanged, compared to its average volume of 56,781. Neonc Technologies has a 52-week low of $3.20 and a 52-week high of $25.00. The company has a 50-day simple moving average of $9.44 and a two-hundred day simple moving average of $9.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neonc Technologies in a report on Monday, December 29th. Zacks Research upgraded Neonc Technologies to a “hold” rating in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Neonc Technologies

Several institutional investors and hedge funds have recently modified their holdings of the company. 683 Capital Management LLC purchased a new stake in Neonc Technologies in the 4th quarter worth approximately $442,000. OMERS ADMINISTRATION Corp acquired a new position in Neonc Technologies in the 4th quarter valued at $126,000. Barclays PLC lifted its stake in shares of Neonc Technologies by 5,314.8% during the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after purchasing an additional 8,982 shares during the period. State Street Corp boosted its holdings in shares of Neonc Technologies by 9.9% during the fourth quarter. State Street Corp now owns 43,170 shares of the company’s stock worth $357,000 after purchasing an additional 3,900 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Neonc Technologies during the fourth quarter worth $124,000.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.